MASH Treatment Options in 2026: What Hepatologists Now Have Beyond Lifestyle Changes

The landscape of MASH treatment has shifted dramatically. Hepatologists now have access to multiple drug classes showing genuine promise in reversing liver scarring, not just slowing it. For patients with moderate to advanced fibrosis—the stage where liver damage becomes most dangerous—pharmaceutical intervention is no longer theoretical. It’s happening now, in clinical trials that are delivering results strong enough to reshape how we think about treating this silent epidemic.

Understanding MASH and Why It Matters
MASH begins innocuously: fat accumulates in the liver, a condition called steatosis. Most people with fatty livers never develop problems. But when inflammation enters the picture—triggered by obesity, insulin resistance, or metabolic dysfunction—the disease progresses. That inflammation causes fibrosis, the scarring that transforms MASH from a benign condition into one that threatens organ failure.

The stakes are real. 35% of Americans with MASH have moderate to advanced fibrosis (stages F2 to F3), meaning their livers are already scarred. Fibrosis stage is the strongest predictor of liver-related outcomes. A patient with F3 fibrosis faces a fundamentally different prognosis than someone with simple steatosis. The mean annual per-patient cost of MASH approaches $20,000, a figure that climbs steeply once cirrhosis develops.

This is where the commercial calculus shifts. Treating MASH early, before cirrhosis, is cheaper and more effective than waiting for end-stage liver disease. Insurers, health systems, and patients themselves are beginning to recognize that pharmaceutical intervention at the fibrosis stage represents a genuine cost-benefit opportunity.

Resmetirom: The First FDA-Approved MASH Drug
In March 2024, resmetirom—a thyroid hormone receptor-β (THR-β) agonist—became the first drug the FDA approved specifically for MASH. The approval was not routine; it came through the accelerated pathway, based on data from the MAESTRO-NASH-OUTCOMES trial, a 52-week study that demonstrated statistically meaningful histologic improvement.

The numbers matter. In the trial, resmetirom achieved:

* MASH resolution without worsening fibrosis: 26% to 30% (compared to 10% with placebo)
* Fibrosis improvement without worsening MASH: 24% to 26% (compared to 14% with placebo)

This isn’t a marginal improvement. A 2.5-fold increase in fibrosis improvement over placebo represents a genuine therapeutic effect. For a hepatologist, these results justified moving resmetirom from research to routine practice.

Dosing is weight-based: 100 mg once daily for patients weighing 100 kg or more, and 80 mg once daily for lighter patients. The drug must be paired with lifestyle interventions—diet, exercise, weight loss—not as a replacement for them.

Who Should Get Resmetirom?
Patient selection is critical. Resmetirom is indicated for adults with confirmed or strongly suspected MASH with fibrosis stages F2 to F3. This specificity matters because it’s not a drug for everyone with fatty liver disease. It’s for those whose livers are already scarred enough to warrant intervention.

Diagnosis relies on noninvasive liver disease assessment (NILDA) techniques, which have become the standard of care. Vibration-controlled transient elastography (VCTE) and magnetic resonance elastography (MRE) provide superior accuracy in fibrosis staging compared to older imaging methods.

Contraindications are equally important: resmetirom is not recommended for patients with symptomatic gallbladder disease, active hepatotoxicity, or abnormal thyroid function that hasn’t been stabilized. The 58-year-old woman described in the clinical literature who presented with acute cholecystitis and MASH cirrhosis would not be a candidate until her gallbladder disease was resolved.

Side Effects and Monitoring
The most common adverse effects are gastrointestinal: diarrhea (24% to 34%) and nausea (12% to 22%). These are manageable but real—the kind of side effects that matter when counseling patients about whether to start therapy.

Monitoring requires periodic assessment. A 25% or greater reduction in VCTE LSM (liver stiffness measurement) or 20% or greater reduction in MRE LSM at 12 months may suggest fibrosis improvement. This gives hepatologists a quantifiable target and patients a timeline for reassessment.

GLP-1 Receptor Agonists: Semaglutide and Beyond
The MASH treatment story took another turn in August 2025 when the FDA approved semaglutide (Wegovy) for MASH in adults with excessive scar tissue in the liver. This approval was significant not because semaglutide was designed for MASH—it wasn’t—but because it works.

The Stravitz-Sanyal Institute for Liver Disease and Metabolic Health at VCU participated in the groundbreaking international trial that demonstrated semaglutide’s efficacy. The drug’s mechanism is indirect: it promotes weight loss and improves metabolic function, both of which reduce liver fat and inflammation.

Research shows that losing as little as 10% of body weight after one year can reverse liver scarring and organ damage. Semaglutide achieves this weight loss reliably. In clinical trials, tirzepatide (another GLP-1 receptor agonist) resolved MASH in nearly 62% of participants, a response rate that rivals or exceeds what we see with direct-acting hepatic therapies.

Semaglutide is also being tested in combination with other drugs—specifically cilofexor and firsocostat—to see if multi-drug approaches yield better outcomes than monotherapy. Early data suggest synergistic effects, though these combinations remain investigational.

Emerging Therapies: FGF21 Analogs and Beyond
FGF21 analogs represent an entirely different mechanism. These drugs mimic fibroblast growth factor 21, a hormone the body naturally produces to regulate metabolism and reduce liver inflammation. Two candidates are in advanced trials:

Efruxifermin: Over approximately two years of treatment, efruxifermin helped 39% of patients with MASH and cirrhosis improve their liver scarring—a remarkable finding, since cirrhosis has historically been considered irreversible.

Pegozafermin: The FDA granted this drug a “Breakthrough Therapy” designation in 2023 based on trial results so compelling that the agency fast-tracked its development path.

Survodutide and Dual GIP/GLP-1 Agonists
Survodutide, a dual GIP/GLP-1 receptor agonist, has shown exceptional promise. Initial findings revealed that up to 83% of participants experienced improvements in liver fat and inflammation, with around 85% of obese participants with fatty liver disease experiencing significant reduction in liver fat. These are among the highest response rates observed in any MASH trial to date.

The Lifestyle Intervention Reality
Despite the pharmaceutical advances, hepatologists continue to emphasize lifestyle change. No drug replaces diet, exercise, and weight loss. The most effective MASH treatment protocols combine pharmacotherapy with behavioral intervention.

The case study of the 58-year-old woman illustrates this point. She lost 19 kg over three months through diet and exercise alone—a 10% reduction in body weight that can reverse fibrosis independently. Medications amplify this effect; they don’t replace it.

Timeline and Cost Considerations
If current clinical trials succeed, the first approved drugs to reverse cirrhosis could arrive in just a few years. This timeline matters for patients and payers. A drug that reverses cirrhosis changes the entire economics of liver disease management.

Cost remains a consideration. Resmetirom, like most specialty pharmaceuticals, will carry a significant price tag. Understanding that MASH costs approximately $20,000 per patient annually provides context: if a drug prevents progression to cirrhosis or reverses existing fibrosis, the ROI is substantial.

Making the Treatment Decision
For hepatologists and their patients, the question is no longer whether to treat MASH—it’s which patients to treat and with what. The presence of F2-F3 fibrosis is the key threshold. Patients below that level may benefit from aggressive lifestyle intervention alone. Those with confirmed fibrosis should now be offered pharmacotherapy alongside lifestyle changes.

The choice between resmetirom, semaglutide, investigational FGF21 analogs, or combination approaches depends on individual patient factors: comorbidities, tolerability, access, and insurance coverage. But for the first time in hepatology, we’re choosing between multiple effective options rather than explaining why we have none.